Published in Cancer Res on July 15, 2007
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate Cancer. Dev Cell (2017) 1.40
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16
RhoGDIα-dependent balance between RhoA and RhoC is a key regulator of cancer cell tumorigenesis. Mol Biol Cell (2011) 1.00
Proteoglycans in prostate cancer. Nat Rev Urol (2012) 0.99
A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene (2008) 0.92
A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J Neurosci (2011) 0.90
Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate (2013) 0.89
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res (2008) 0.87
Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone Marrow Res (2014) 0.84
SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer (2014) 0.83
Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone. J Biol Chem (2016) 0.82
Bone matrix osteonectin limits prostate cancer cell growth and survival. Matrix Biol (2012) 0.82
Augmented osteolysis in SPARC-deficient mice with bone-residing prostate cancer. Neoplasia (2011) 0.81
Expression profiling using a cDNA array and immunohistochemistry for the extracellular matrix genes FN-1, ITGA-3, ITGB-5, MMP-2, and MMP-9 in colorectal carcinoma progression and dissemination. ScientificWorldJournal (2014) 0.80
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin. Biochemistry (2011) 0.79
Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth. PLoS One (2016) 0.75
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One (2017) 0.75
Matricellular proteins as regulators of cancer metastasis to bone. Matrix Biol (2016) 0.75
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Osteonectin, a bone-specific protein linking mineral to collagen. Cell (1981) 4.06
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem (1984) 2.01
Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol (2001) 1.95
Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest (2000) 1.70
Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res (1999) 1.57
Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res (2000) 1.52
Molecular pathway for cancer metastasis to bone. J Biol Chem (2003) 1.47
Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res (2001) 1.43
Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res (2006) 1.19
Prostate carcinoma bone-stroma interaction and its biologic and therapeutic implications. Cancer (2003) 1.18
Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol (2004) 1.03
Functional analysis of the matricellular protein SPARC with novel monoclonal antibodies. J Histochem Cytochem (2004) 0.99
Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. Semin Cancer Biol (1993) 0.97
Expression and purification of recombinant human SPARC produced by baculovirus. Mol Cell Biol Res Commun (2000) 0.95
Over-expression of bone sialoprotein enhances bone metastasis of human breast cancer cells in a mouse model. Int J Oncol (2003) 0.92
Expression of recombinant MDA-BF-1 with a kinase recognition site and a 7-histidine tag for receptor binding and purification. Protein Expr Purif (2005) 0.89
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol (2002) 4.23
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
SPARC and tumor growth: where the seed meets the soil? J Cell Biochem (2004) 2.75
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A (2006) 2.59
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res (2003) 2.08
SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res (2005) 2.07
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab (2005) 1.99
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity. J Biol Chem (2005) 1.70
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res (2012) 1.68
SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem (2007) 1.68
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest (2003) 1.67
Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proc Natl Acad Sci U S A (2011) 1.65
Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med (2008) 1.62
Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res (2004) 1.59
Lumbar intervertebral disc degeneration associated with axial and radiating low back pain in ageing SPARC-null mice. Pain (2012) 1.58
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell (2003) 1.55
Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res (2004) 1.54
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol (2006) 1.53
Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech (2009) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
A prototypic matricellular protein in the tumor microenvironment--where there's SPARC, there's fire. J Cell Biochem (2008) 1.50
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Molecular pathway for cancer metastasis to bone. J Biol Chem (2003) 1.47
SPARC-null mice exhibit accelerated cutaneous wound closure. J Histochem Cytochem (2002) 1.47
Fractal analysis of region-based vascular change in the normal and non-proliferative diabetic retina. Curr Eye Res (2002) 1.47
Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42
Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
Osteonectin-null mutation compromises osteoblast formation, maturation, and survival. Endocrinology (2003) 1.37
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med (2012) 1.35
Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol (2003) 1.35
SPARC inhibits adipogenesis by its enhancement of beta-catenin signaling. J Biol Chem (2008) 1.34
A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen (2006) 1.33
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity (2006) 1.33
A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32
Histone deacetylase 3 localizes to the mitotic spindle and is required for kinetochore-microtubule attachment. Proc Natl Acad Sci U S A (2008) 1.30
Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis. Breast Cancer Res (2008) 1.30
NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol (2006) 1.30
Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29
SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem (2010) 1.29
The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem (2008) 1.27
Compositional differences between infant and adult human corneal basement membranes. Invest Ophthalmol Vis Sci (2007) 1.25
SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem (2004) 1.24
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22
Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res (2008) 1.22
Role for NudC, a dynein-associated nuclear movement protein, in mitosis and cytokinesis. J Cell Sci (2003) 1.21